Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9000216 | 0.85 | ALDH1A1 (0.30) | ALDH1A1 | |
| SCHEMBL10319334 | 0.85 | ALDH1A1 (0.30) | ALDH1A1 | |
| SCHEMBL22897549 | 0.82 | — | — | |
| SCHEMBL11678695 | 0.78 | EPHX1 (0.36) | ALDH1A1 | |
| SCHEMBL11677537 | 0.77 | FAAH (0.34) | ALDH1A1 | |
| SCHEMBL11674144 | 0.76 | KMT2A (0.43) | ALDH1A1 | |
| SCHEMBL6560042 | 0.76 | CRBN (0.35) | — | |
| SCHEMBL6560044 | 0.76 | CRBN (0.35) | — | |
| SCHEMBL10170621 | 0.76 | CRBN (0.35) | — | |
| SCHEMBL13648040 | 0.76 | MMP1 (0.34) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9937192-B2 | Combination therapy to treat mycobacterium diseases | SPERO TRINEM, INC. (US) | 2018-04-10 | — | — | US | disclosed |
| US-20170128471-A1 | COMBINATION THERAPY TO TREAT MYCOBACTERIUM DISEASES | SPERO THERAPEUTICS, INC. | 2017-05-11 | — | — | US | disclosed |
| US-9572809-B2 | Combination therapy to treat Mycobacterium diseases | SPERO TRINEM, INC. (US) | 2017-02-21 | — | — | US | disclosed |
| US-9125922-B2 | Phosphate esters of gyrase and topoisomerase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-09-08 | — | — | US | disclosed |
| US-9040542-B2 | Solid forms of gyrase inhibitor (R)-1-ethyl-3-[6-fluoro-5-[2-(1-hydroxy-1-methyl-ethyl)pryimidin-5-yl]-7-(tetrahydrofuran-2-yl)-1H-benzimidazol-2-yl]urea | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-05-26 | — | — | US | disclosed |
| US-9018216-B2 | Solid forms of (R)-2-(5-(2-(3-ethylureido)-6-fluoro-7-(tetrahydrofuran-2-yl)-1H-benzo[d]imidazol-5-yl)pyrimidin-2-yl)propan-2-yl dihydrogen phosphate and salts thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-04-28 | — | — | US | disclosed |
| US-8969359-B2 | Gyrase and topoisomerase IV inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-03-03 | — | — | US | disclosed |
| US-8912326-B2 | Process of making gyrase and topoisomerase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-12-16 | — | — | US | disclosed |
| US-20140045791-A1 | COMBINATION THERAPY TO TREAT MYCOBACTERIUM DISEASES | SPERO THERAPEUTICS, INC. | 2014-02-13 | — | — | US | disclosed |
| US-20140031318-A1 | SOLID FORMS OF (R)-2-(5-(2-(3-ETHYLUREIDO)-6-FLUORO-7-(TETRAHYDROFURAN-2-YL)-1H-BENZO[d]IMIDAZOL-5-YL)PYRIMIDIN-2-YL)PROPAN-2-YL DIHYDROGEN PHOSPHATE AND SALTS THEREOF | SPERO THERAPEUTICS, INC. | 2014-01-30 | — | — | US | disclosed |
| US-8481552-B2 | Solid forms of gyrase inhibitor (R)-1-ethyl-3-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-YL]-7-(tetrahydrofuran-2-yl)-1H-benzimidazol-2-YL]urea | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-09 | — | — | US | disclosed |
| US-8481551-B2 | Gyrase and topoisomerase IV inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-09 | — | — | US | disclosed |
| US-8476281-B2 | Solid forms of gyrase inhibitor (R)-1-ethyl-3-[6-fluoro-5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-(tetrahydrofuran-2-yl)-1H-benzimidazol-2-yl]urea | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-02 | — | — | US | disclosed |
| US-8471014-B2 | Process of making gyrase and topoisomerase IV inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-06-25 | — | — | US | disclosed |
| US-8471014-B2 | Process of making gyrase and topoisomerase IV inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-06-25 | — | — | US | disclosed |
| US-20130157979-A1 | PHOSPHATE ESTERS OF GYRASE AND TOPOISOMERASE INHIBITORS | SPERO THERAPEUTICS, INC. | 2013-06-20 | — | — | US | disclosed |
| US-20120184742-A1 | PROCESS OF MAKING GYRASE AND TOPOISOMERASE IV INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120184512-A1 | GYRASE AND TOPOISOMERASE IV INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120184741-A1 | SOLID FORMS OF GYRASE INHIBITOR (R)-1-ETHYL-3-[5-[2-(1-HYDROXY-METHYL-ETHYL)PYRIMIDIN-5-YL]-7-(TETRAHYDROFURAN-2-YL)-1H-BENZIMIDAZOL-2-YL]UREA | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120184564-A1 | SOLID FORMS OF GYRASE INHIBITOR (R)-1-ETHYL-3-[6-FLUORO-5-[2-(1-HYDROXY-1-METHYL-ETHYL)PYRIMIDIN-5-YL]-7-(TETRAHYDROFURAN-2-YL)-1H-BENZIMIDAZOL-2-YL]UREA | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140031318-A1 | SOLID FORMS OF (R)-2-(5-(2-(3-ETHYLUREIDO)-6-FLUORO-7-(TETRAHYDROFURAN-2-YL)-1H-BENZO[d]IMIDAZOL-5-YL)PYRIMIDIN-2-YL)PROPAN-2-YL DIHYDROGEN PHOSPHATE AND SALTS THEREOF | KCNJ2, KCNN4, CACNA1A | ALDH1A1 1865/4885 |
| US-20170128471-A1 | COMBINATION THERAPY TO TREAT MYCOBACTERIUM DISEASES | TOP1, TOP2A, TOP2B | ALDH1A1 1768/4885 |
| US-20140045791-A1 | COMBINATION THERAPY TO TREAT MYCOBACTERIUM DISEASES | TOP1, TOP2A, TOP2B | ALDH1A1 1768/4885 |
| US-20120184742-A1 | PROCESS OF MAKING GYRASE AND TOPOISOMERASE IV INHIBITORS | TOP1, TOP2A, TOP2B | ALDH1A1 3589/4885 |
| US-20130157979-A1 | PHOSPHATE ESTERS OF GYRASE AND TOPOISOMERASE INHIBITORS | TOP1, TOP2A, TOP2B | ALDH1A1 3745/4885 |
| US-20120184512-A1 | GYRASE AND TOPOISOMERASE IV INHIBITORS | TOP1, TOP2A, TOP2B | ALDH1A1 2840/4885 |
| US-20120184564-A1 | SOLID FORMS OF GYRASE INHIBITOR (R)-1-ETHYL-3-[6-FLUORO-5-[2-(1-HYDROXY-1-METHYL-ETHYL)PYRIMIDIN-5-YL]-7-(TETRAHYDROFURAN-2-YL)-1H-BENZIMIDAZOL-2-YL]UREA | TOP1, TOP2A, TOP2B | ALDH1A1 2070/4885 |
| US-20120184741-A1 | SOLID FORMS OF GYRASE INHIBITOR (R)-1-ETHYL-3-[5-[2-(1-HYDROXY-METHYL-ETHYL)PYRIMIDIN-5-YL]-7-(TETRAHYDROFURAN-2-YL)-1H-BENZIMIDAZOL-2-YL]UREA | TOP1, TOP2A, TOP2B | ALDH1A1 2926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.